Novo links up with Hengrui Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 29 September, 2026

The entire healthcare ecosystem is more Silicon Valley-ified than ever before. What tech has actually changed? Is biopharma behind? Find out, join us for Health Tech day.

news Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug AstraZeneca buys a $2B stake in Summit, taking equity in bet on cancer drug Exclusive: Swedish biotech AnaCardio raises $70.9M for 'safer' heart drug Egetis Therapeutics' Emcitate cleared by FDA for rare X-linked genetic disease

Oct 08 11:00 am ET Site-central discordance in oncology trial imaging: New benchmarks and management strategies sponsored by Perceptive Imaging Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

Vice President, Regulatory Affairs Hinge Bio, Inc. Redwood City, CA, USA Team Leader, Analytical Research & Development (ARD) Veranova Devens, MA 01434, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

ENDPOINTS PHARMA White House takes stock of US-based manufacturing for 86 essential drugs Nonprofits' gene therapy for ultra-rare immune disease will cost $3.25M Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer

in case you missed it 1. Mirum notches first Phase 3 victory for its acquired hepatitis delta treatment 2. Adicet Bio shares promising look at CAR-T for lupus, but stock drops anyway 3. Roche cans muscle-preserving obesity drug, hands it back to Chugai 4. Kodiak's stock soars as it clinches crucial Phase 3 win for Eylea competitor